Safety, Efficacy and Pharmacokinetics of CBT-008 in Patients With Meibomian Gland Dysfunction

NCT05261386 | Completed Phase 2 Results FDA Drug

• 1 other identifier: CBT-CS-105
• Study Type: interventional
• Target: 95
• Locations: 1 country
• Sites: 1

Brief Summary

Study Design Structure: Multicenter, randomized, double-masked, vehicle-controlled, parallel group study Duration: 1 month of TID treatment Treatment Groups, Dosing, and Treatment Regimen Study Treatment: CBT-008 topical ophthalmic solution Control Treatment: CBT-008 vehicle

Conditions

Meibomian Gland Dysfunction

Outcome Measures

Primary Outcomes (1)

• IOP Related to Safety

  Intraocular Pressure for study eye

  4 weeks

Study Arms (3)

Placebo Comparator: CBT-008

PLACEBO COMPARATOR

Vehicle

Drug: CBT-008

Experimental: CBT-008 lower concentration

EXPERIMENTAL

lower concentration dose

Drug: CBT-008

Experimental: CBT-008 higher concentration

EXPERIMENTAL

higher concentration dose

Drug: CBT-008

Interventions

CBT-008 DRUG

Treat MGD

Experimental: CBT-008 higher concentration; Experimental: CBT-008 lower concentration; Placebo Comparator: CBT-008

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosed with MGD in both eyes and meet the following:
• Ocular discomfort Score (ODS) ≥ 2 (No discomfort = 0, slight discomfort = 1, mild discomfort = 2, moderate discomfort = 3, severe discomfort = 4)
• Visual Analog Scale (VAS) level is 35-90% for at least 1 of the 7 categories
• Total Cornea staining grade ≥ 3 (NEI scheme with max score = 15)
• Total meibum quality score (MQS) is between 6-17 from the sum of the 6 lower eyelid central glands in at least one lower eyelid (0-3 scale with max total = 18).
• TBUT ≤ 5 s
• Schirmer I Test (anaesthetized) ≥ 5 mm/5 min in study eye
• BCVA LogMAR ≥ +0.7 in each eye
• All patients of both genders ≥ 18 years
• Willing to withhold the use of artificial tears and lubricants during the treatment phase;
• Able to provide written informed consent and comply with study assessments for the full duration of the study.
• Patients who completed the Stage 1 Exit Visit for at least 1 month or healthy volunteers
• At least 18 years of age at time of consent and able to provide written informed consent

You may not qualify if:

• Uncontrolled systemic disease in the opinion of the Investigator
• Active allergies with symptoms that may confound the data, active ocular infection requiring treatment, or ocular surface inflammatory disease unrelated to MGD or DED, including chalazion, inflamed pinguecula, and viral illness
• History of ocular herpes disease in either eye
• Incisional ocular surgery within 6 months or ocular laser surgery within 3 months
• Use of topical treatment of the eye/eyelid with antibiotics, NSAIDS, or vasoconstrictors to treat MGD or DED within 14 days of screening; steroids, cyclosporin A or lifitegrast within 28 days of screening
• Current or anticipated use of other topical ophthalmic medications in the study eye. (Patients must have discontinued the use of ophthalmic medications in the study eye for at least 2 weeks prior to the screening visit, the use of diagnostic medications as part of the eye exam prior to screening and artificial tears is allowed.)
• Anticipated wearing of contact lenses during any portion of the study. (Patients, who wear soft contact lenses should discontinue wearing them at least 3 days prior to screening visit. Patients wearing rigid gas permeable or hard contact lenses should discontinue wearing them at least 3 weeks prior to screening visit.)
• Active rosacea involving the eyelids within 60 days of screening
• Current enrollment in an investigational drug or device study or participation in such a study within 30 days prior to entry into this study
• Any condition or situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study
• Females who were pregnant or nursing
• Current enrollment in an investigational drug or device study or participation in such a study within 30 days prior to entry into this study
• Previously randomized in the CBT-CS102 clinical trial and dosed with CBT-006

Sponsors & Collaborators

• Cloudbreak Therapeutics, LLC: lead

Study Sites (1)

David Research Wirta

Newport Beach, California, 92663, United States

Location

MeSH Terms

Conditions

Meibomian Gland Dysfunction

Condition Hierarchy (Ancestors)

Eyelid Diseases; Eye Diseases

Results Point of Contact

• Title: Dr. Rong Yang
• Organization: ADS Therapeutics LLC

rong_yang@cloudbreaktherapeutics.com

9496798408

Study Officials

• Bing Leng, MD

  ADS Therapeutics, LLC

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 20, 2022
• First Posted: March 2, 2022
• Study Start: March 4, 2022
• Primary Completion: September 7, 2022
• Study Completion: March 29, 2023
• Last Updated: April 24, 2024
• Results First Posted: April 24, 2024

Record last verified: 2022-02

Locations

US (1)